Open AccessAnalysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies
Author(s) -
Shumei Kato,
Jeffrey S. Ross,
Laurie M. Gay,
Farshid Dayyani,
Jason Roszik,
Vivek Subbiah,
Razelle Kurzrock
Publication year - 2018
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.17.00235
Subject(s) - mdm2 , gene duplication , cancer research , cancer , carcinogenesis , population , biology , gene , medicine , oncology , bioinformatics , genetics , environmental health
MDM2 amplification can promote tumorigenesis directly or indirectly through p53 inhibition. MDM2 has increasing clinical relevance because inhibitors are under evaluation in clinical trials, and MDM2 amplification is a possible genomic correlate of accelerated progression, known as hyperprogression, after anti-PD-1/PD-L1 immunotherapy. We used next-generation sequencing (NGS) to ascertain MDM2 amplification status across a large number of diverse cancers.